Hangzhou Tigermed Consulting (03347): As of the end of July, a total of 20.963 million A-shares have been repurchased.
Tigermed Pharmaceutical (03347) announced that as of July 31, 2026, the company has repurchased 20.963 million shares through a special securities account for share repurchase via centralized bidding transactions, accounting for 2.4347% of the company's current total share capital and 2.8410% of the company's current total A-share capital. The highest transaction price was 42.78 yuan per share, and the lowest transaction price was 38.22 yuan per share, with a total transaction amount of 824 million yuan (excluding transaction fees).
Hangzhou Tigermed Consulting (03347) announced that as of July 31, 2026, the company repurchased 20.963 million shares through a dedicated securities account for share buybacks via centralized bidding, representing 2.4347% of the current total share capital of the company and 2.8410% of the current total share capital of the company's A-shares. The highest transaction price was 42.78 yuan per share, the lowest transaction price was 38.22 yuan per share, and the total transaction amount was 824 million yuan (excluding transaction fees).
Related Articles
Sungrow Power Supply (300274.SZ) plans to repurchase the company's shares for 500 million to 1 billion yuan.
ASIA STRAT TECH (01027): The trading unit for each hand will be changed to 1,000 shares.
REMEGEN (09995): As of the end of July, a total of 13,000 A-shares have been repurchased.
Sungrow Power Supply (300274.SZ) plans to repurchase the company's shares for 500 million to 1 billion yuan.
ASIA STRAT TECH (01027): The trading unit for each hand will be changed to 1,000 shares.
REMEGEN (09995): As of the end of July, a total of 13,000 A-shares have been repurchased.
RECOMMEND
